Pub Date : 2025-06-01DOI: 10.1016/j.endien.2025.501577
Tomás González-Vidal , Diego Rivas-Otero , Carmen Lambert , Jessica Ares Blanco , Elías Delgado-Álvarez , Edelmiro Menéndez Torre
Objective
To predict the length of hospital stay in hyperosmolar hyperglycemic crises (HHC) using variables available on admission.
Methods
We conducted a retrospective cohort study with 132 patients (65 [49.2%] men; median age 72 years; range 19–98 years) hospitalized for HHC (including hyperosmolar hyperglycemic state and diabetic ketoacidosis with elevated osmolality) in a Spanish teaching hospital. Baseline variables and those upon arrival to the emergency department were collected (both variables related to physical examination and biochemical tests), as well as the in-hospital mortality rate and overall length of hospital stay in survivors.
Results
Patients who died (n = 13) had higher total serum osmolality and higher C-reactive protein concentrations on admission vs survivors. Among survivors, the length of stay correlated positively with total serum osmolality (Rho = 0.398; p < 0.001) and C-reactive protein (Rho = 0.342; p < 0.001) on admission. Older age, female sex, lack of pre-admission diagnosis of insulin-requiring diabetes, impaired mental status on arrival, non-ketotic metabolic acidosis, and low serum potassium concentrations were also associated with long lengths of stay. In multivariate analysis, only serum glucose (one of the three components of total osmolality) and C-reactive protein concentrations on admission kept a positive association with the length of stay.
Conclusions
Hyperglycemia and elevated C-reactive protein on admission are independent predictors of long lengths of stay in survivors with HHC.
{"title":"Predictors of length of hospital stay in patients presenting to the emergency department with hyperosmolar hyperglycemic crises","authors":"Tomás González-Vidal , Diego Rivas-Otero , Carmen Lambert , Jessica Ares Blanco , Elías Delgado-Álvarez , Edelmiro Menéndez Torre","doi":"10.1016/j.endien.2025.501577","DOIUrl":"10.1016/j.endien.2025.501577","url":null,"abstract":"<div><h3>Objective</h3><div>To predict the length of hospital stay in hyperosmolar hyperglycemic crises (HHC) using variables available on admission.</div></div><div><h3>Methods</h3><div>We conducted a retrospective cohort study with 132 patients (65 [49.2%] men; median age 72 years; range 19–98 years) hospitalized for HHC (including hyperosmolar hyperglycemic state and diabetic ketoacidosis with elevated osmolality) in a Spanish teaching hospital. Baseline variables and those upon arrival to the emergency department were collected (both variables related to physical examination and biochemical tests), as well as the in-hospital mortality rate and overall length of hospital stay in survivors.</div></div><div><h3>Results</h3><div>Patients who died (<em>n</em> <!-->=<!--> <!-->13) had higher total serum osmolality and higher C-reactive protein concentrations on admission vs survivors. Among survivors, the length of stay correlated positively with total serum osmolality (Rho<!--> <!-->=<!--> <!-->0.398; <em>p</em> <!--><<!--> <!-->0.001) and C-reactive protein (Rho<!--> <!-->=<!--> <!-->0.342; <em>p</em> <!--><<!--> <!-->0.001) on admission. Older age, female sex, lack of pre-admission diagnosis of insulin-requiring diabetes, impaired mental status on arrival, non-ketotic metabolic acidosis, and low serum potassium concentrations were also associated with long lengths of stay. In multivariate analysis, only serum glucose (one of the three components of total osmolality) and C-reactive protein concentrations on admission kept a positive association with the length of stay.</div></div><div><h3>Conclusions</h3><div>Hyperglycemia and elevated C-reactive protein on admission are independent predictors of long lengths of stay in survivors with HHC.</div></div>","PeriodicalId":48650,"journal":{"name":"Endocrinologia Diabetes Y Nutricion","volume":"72 6","pages":"Article 501577"},"PeriodicalIF":1.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144263597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-05-01DOI: 10.1016/j.endien.2025.101532
Juan J. Díez
{"title":"New therapeutic options in the management of chronic hypoparathyroidism","authors":"Juan J. Díez","doi":"10.1016/j.endien.2025.101532","DOIUrl":"10.1016/j.endien.2025.101532","url":null,"abstract":"","PeriodicalId":48650,"journal":{"name":"Endocrinologia Diabetes Y Nutricion","volume":"72 5","pages":"Article 101532"},"PeriodicalIF":1.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144081275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-05-01DOI: 10.1016/j.endien.2025.501579
María Carmen López García , Andrés Ruiz de Assin Valverde , Alejandro Sirvent Segovia , Cristina Lamas Oliveira , José Joaquín Alfaro Martínez
{"title":"Adrenal hemorrhage: Case series and review of their management","authors":"María Carmen López García , Andrés Ruiz de Assin Valverde , Alejandro Sirvent Segovia , Cristina Lamas Oliveira , José Joaquín Alfaro Martínez","doi":"10.1016/j.endien.2025.501579","DOIUrl":"10.1016/j.endien.2025.501579","url":null,"abstract":"","PeriodicalId":48650,"journal":{"name":"Endocrinologia Diabetes Y Nutricion","volume":"72 5","pages":"Article 501579"},"PeriodicalIF":1.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144086516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-05-01DOI: 10.1016/j.endien.2025.501560
Elena González Arnáiz , Juan José López Gómez , Diana Ariadel Cobo , Brisamar Estébanez , María García Duque , Carmen Dameto Pons , David Barajas Galindo , Diana García Sastre , Ana Urioste Fondo , María J. Cuevas , María D. Ballesteros Pomar
Background
Hand grip strength—measured by dynamometry—is an essential tool in nutritional assessment, particularly for detecting sarcopenia, even before weight or muscle mass loss is evident. In individuals with obesity, hand grip strength can help identify muscle weakness that may not be apparent due to high body mass. The purpose of this study is to describe the absolute and adjusted hand grip strength values for weight, height, body mass index (BMI), and appendicular skeletal muscle mass (ASMM) in obese patients. It also aims to determine the prevalence of low muscle strength in this group of patients and to compare these results with those obtained in a healthy population.
Methods
Prospective observational study including patients with obesity and healthy volunteers. Absolute and adjusted hand grip strength values for weight, height, BMI and appendicular muscle mass were determined in patients with obesity and compared with the results of healthy volunteers. Muscle strength was measured by hand grip strength according to Sánchez-Torralvo, Dodds, and < −2SD cut-off points of healthy reference population.
Results
The results obtained show that the absolute hand grip strength values are higher in healthy volunteers (30.7 ± 10.5 kg) vs patients with obesity (26.6 ± 9.7 kg); p < 0.008. As for hand grip strength values adjusted for height, weight, BMI and ASMM, they are also statistically significantly higher in healthy volunteers (18.0 ± 5.5 vs. 15.9 ± 5.4, p < 0.014; 05 ± 0.10 vs. 0.2 ± 0.06, p < 0.001; 1.4 ± 0.4 vs. 0.6 ± 0.2, p < 0.001; 1.5 ± 0.2 vs. 0.9 ± 0.3, p < 0.001). According to sex, men had significantly higher absolute and adjusted hand grip strength values in both obese patients and healthy volunteers. The prevalence of low muscle strength in patients with obesity goes from 14.5% up and 23.4% depending on the cut-off points used, being higher with those of Sánchez-Torralvo´s cut-off points. Based on sex distribution, obese men had a higher prevalence of low muscle strength with absolute hand grip strength values vs women, being these differences statistically significant only with the Sánchez-Torralvo´s cut-off points. In terms of the prevalence of low muscle strength with adjusted hand grip strength values, more variable percentages (3.2%–96.8%) were observed without clear differences across sexes.
Conclusions
Hand grip strength values in obese patients vary according to absolute or adjusted measurements. Obese patients have lower absolute and adjusted hand grip strength values vs the healthy population. However, more studies are needed to establish specific cut-off points for hand grip strength in patients with obesity.
{"title":"Absolute and adjusted hand grip strength values in obese patients","authors":"Elena González Arnáiz , Juan José López Gómez , Diana Ariadel Cobo , Brisamar Estébanez , María García Duque , Carmen Dameto Pons , David Barajas Galindo , Diana García Sastre , Ana Urioste Fondo , María J. Cuevas , María D. Ballesteros Pomar","doi":"10.1016/j.endien.2025.501560","DOIUrl":"10.1016/j.endien.2025.501560","url":null,"abstract":"<div><h3>Background</h3><div>Hand grip strength—measured by dynamometry—is an essential tool in nutritional assessment, particularly for detecting sarcopenia, even before weight or muscle mass loss is evident. In individuals with obesity, hand grip strength can help identify muscle weakness that may not be apparent due to high body mass. The purpose of this study is to describe the absolute and adjusted hand grip strength values for weight, height, body mass index (BMI), and appendicular skeletal muscle mass (ASMM) in obese patients. It also aims to determine the prevalence of low muscle strength in this group of patients and to compare these results with those obtained in a healthy population.</div></div><div><h3>Methods</h3><div>Prospective observational study including patients with obesity and healthy volunteers. Absolute and adjusted hand grip strength values for weight, height, BMI and appendicular muscle mass were determined in patients with obesity and compared with the results of healthy volunteers. Muscle strength was measured by hand grip strength according to Sánchez-Torralvo, Dodds, and < −2SD cut-off points of healthy reference population.</div></div><div><h3>Results</h3><div>The results obtained show that the absolute hand grip strength values are higher in healthy volunteers (30.7 ± 10.5 kg) vs patients with obesity (26.6 ± 9.7 kg); p < 0.008. As for hand grip strength values adjusted for height, weight, BMI and ASMM, they are also statistically significantly higher in healthy volunteers (18.0 ± 5.5 vs. 15.9 ± 5.4, p < 0.014; 05 ± 0.10 vs. 0.2 ± 0.06, p < 0.001; 1.4 ± 0.4 vs. 0.6 ± 0.2, p < 0.001; 1.5 ± 0.2 vs. 0.9 ± 0.3, p < 0.001). According to sex, men had significantly higher absolute and adjusted hand grip strength values in both obese patients and healthy volunteers. The prevalence of low muscle strength in patients with obesity goes from 14.5% up and 23.4% depending on the cut-off points used, being higher with those of Sánchez-Torralvo´s cut-off points. Based on sex distribution, obese men had a higher prevalence of low muscle strength with absolute hand grip strength values vs women, being these differences statistically significant only with the Sánchez-Torralvo´s cut-off points. In terms of the prevalence of low muscle strength with adjusted hand grip strength values, more variable percentages (3.2%–96.8%) were observed without clear differences across sexes.</div></div><div><h3>Conclusions</h3><div>Hand grip strength values in obese patients vary according to absolute or adjusted measurements. Obese patients have lower absolute and adjusted hand grip strength values vs the healthy population. However, more studies are needed to establish specific cut-off points for hand grip strength in patients with obesity.</div></div>","PeriodicalId":48650,"journal":{"name":"Endocrinologia Diabetes Y Nutricion","volume":"72 5","pages":"Article 501560"},"PeriodicalIF":1.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144086514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-05-01DOI: 10.1016/j.endien.2025.501564
Berta Bella Burgos , Ruben Carrera Salas , Ricard Onieva Carbajo , Catalina Padilla Navas , María del Carmen Ramos Guijo , Laura Escudero Larrá , Rosa María Rodríguez Millán , José Antonio Vázquez Luque , Silvia Hurtado Mas , Adrià Asensi Puig , Carmen María Blázquez Mañá , Santi Barcons Vilaplana , Ismail Capel Flores , Xavier Guirao Garriga , Víctor Pérez-Riverola , Mario Prenafeta Moreno , Neus Combalia Soriano , Ruth Orellana Fernández , Joan Carles Ferreres Piñas , María Rosa Bella-Cueto
Introduction
Since the C228T mutation in theTERT promoter (TERTp) has been identified almost exclusively in thyroid malignancies, our objective was to study the usefulness of its determination in thyroid fine needle aspirations (FNA) of the IV category of the Bethesda classification (B.IV).
Methodology
From the FNAs performed between 1993 and 2015, we selected those with a diagnosis of B.IV or equivalent and subsequent thyroidectomy. A retrospective study of the C228T mutation in TERTp was performed by pyrosequencing in neoplastic cases (adenomas, low risk neoplasms and carcinomas), both from the surgical specimen and from the FNA material if feasible.
Results
79 cases with a diagnosis of B.IV were identified, and mutational study was performed in the 61 cases corresponding to neoplasms, identifying 10 cases with the mutation (12.6% of the series), with a higher presence in Poorly Differentiated Carcinomas (PDC) or with a minor PDC component (45%), in cases with death attributable to thyroid carcinoma (50%) and in patients alive but with persistence of thyroid carcinoma (50%). The mutation was confirmed in 7 of 8 cases with the mutation and satisfactory cytological material. In 4 cases, preoperative knowledge of the mutation could have avoided a two-stage thyroidectomy.
Conclusion
The study of the C228T mutation ofTERTp can be useful to detect malignancy and establish the best surgical approach in patients with thyroid FNA with a diagnosis of B.IV.
{"title":"Study of the C228T mutation of the TERT promoter in thyroid aspirative punctures of IV category of the Bethesda classification","authors":"Berta Bella Burgos , Ruben Carrera Salas , Ricard Onieva Carbajo , Catalina Padilla Navas , María del Carmen Ramos Guijo , Laura Escudero Larrá , Rosa María Rodríguez Millán , José Antonio Vázquez Luque , Silvia Hurtado Mas , Adrià Asensi Puig , Carmen María Blázquez Mañá , Santi Barcons Vilaplana , Ismail Capel Flores , Xavier Guirao Garriga , Víctor Pérez-Riverola , Mario Prenafeta Moreno , Neus Combalia Soriano , Ruth Orellana Fernández , Joan Carles Ferreres Piñas , María Rosa Bella-Cueto","doi":"10.1016/j.endien.2025.501564","DOIUrl":"10.1016/j.endien.2025.501564","url":null,"abstract":"<div><h3>Introduction</h3><div>Since the C228T mutation in the<em>TERT</em> promoter (<em>TERTp</em>) has been identified almost exclusively in thyroid malignancies, our objective was to study the usefulness of its determination in thyroid fine needle aspirations (FNA) of the IV category of the Bethesda classification (B.IV).</div></div><div><h3>Methodology</h3><div>From the FNAs performed between 1993 and 2015, we selected those with a diagnosis of B.IV or equivalent and subsequent thyroidectomy. A retrospective study of the C228T mutation in <em>TERTp</em> was performed by pyrosequencing in neoplastic cases (adenomas, low risk neoplasms and carcinomas), both from the surgical specimen and from the FNA material if feasible.</div></div><div><h3>Results</h3><div>79 cases with a diagnosis of B.IV were identified, and mutational study was performed in the 61 cases corresponding to neoplasms, identifying 10 cases with the mutation (12.6% of the series), with a higher presence in Poorly Differentiated Carcinomas (PDC) or with a minor PDC component (45%), in cases with death attributable to thyroid carcinoma (50%) and in patients alive but with persistence of thyroid carcinoma (50%). The mutation was confirmed in 7 of 8 cases with the mutation and satisfactory cytological material. In 4 cases, preoperative knowledge of the mutation could have avoided a two-stage thyroidectomy.</div></div><div><h3>Conclusion</h3><div>The study of the C228T mutation of<em>TERTp</em> can be useful to detect malignancy and establish the best surgical approach in patients with thyroid FNA with a diagnosis of B.IV.</div></div>","PeriodicalId":48650,"journal":{"name":"Endocrinologia Diabetes Y Nutricion","volume":"72 5","pages":"Article 501564"},"PeriodicalIF":1.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144086524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-05-01DOI: 10.1016/j.endien.2025.501562
Fernando Garagoli , Walter Masson , Leandro Barbagelata , Martín Lobo
Objective
To evaluate the effect of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on the risk of major adverse limb events (MALE).
Methods
We conducted a systematic review and meta-analysis of randomized clinical trials assessing the effects of GLP-1RAs therapy on peripheral arterial disease (PAD)-related outcomes in patients with type 2 diabetes mellitus (T2DM). This meta-analysis was performed according to PRISMA guidelines. The random-effects model was performed.
Results
A total of 6 randomized clinical trials were considered eligible for this systematic review. On the other hand, 4 clinical trials were included for the meta-analysis. A total of 15,427 subjects were allocated to the GLP-1RAs group, and 15,476 to the placebo group. Overall, this meta-analysis showed that the use of GLP-1RAs is associated with a lower risk of PAD-related events (OR, 0.78; 95%CI, 0.62–0.98, I2 = 39%) vs the placebo group. The analytical evaluation did not suggest publication bias, and the sensitivity analysis demonstrated that the result was robust.
Conclusion
This meta-analysis demonstrated that the use of GLP-1RAs is associated with fewer PAD-related clinical events. Of note, despite the clinical significance of PAD, most analyzed studies did not specifically report on these events. Future studies should include PAD as a key endpoint. PROSPERO Registration: CRD42024565567.
{"title":"Effect of glucagon-like peptide-1 receptor agonists on the risk of major adverse limb events in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized clinical trials","authors":"Fernando Garagoli , Walter Masson , Leandro Barbagelata , Martín Lobo","doi":"10.1016/j.endien.2025.501562","DOIUrl":"10.1016/j.endien.2025.501562","url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate the effect of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on the risk of major adverse limb events (MALE).</div></div><div><h3>Methods</h3><div>We conducted a systematic review and meta-analysis of randomized clinical trials assessing the effects of GLP-1RAs therapy on peripheral arterial disease (PAD)-related outcomes in patients with type 2 diabetes mellitus (T2DM). This meta-analysis was performed according to PRISMA guidelines. The random-effects model was performed.</div></div><div><h3>Results</h3><div>A total of 6 randomized clinical trials were considered eligible for this systematic review. On the other hand, 4 clinical trials were included for the meta-analysis. A total of 15,427 subjects were allocated to the GLP-1RAs group, and 15,476 to the placebo group. Overall, this meta-analysis showed that the use of GLP-1RAs is associated with a lower risk of PAD-related events (OR, 0.78; 95%CI, 0.62–0.98, <em>I</em><sup>2</sup> <!-->=<!--> <!-->39%) vs the placebo group. The analytical evaluation did not suggest publication bias, and the sensitivity analysis demonstrated that the result was robust.</div></div><div><h3>Conclusion</h3><div>This meta-analysis demonstrated that the use of GLP-1RAs is associated with fewer PAD-related clinical events. Of note, despite the clinical significance of PAD, most analyzed studies did not specifically report on these events. Future studies should include PAD as a key endpoint. PROSPERO Registration: CRD42024565567.</div></div>","PeriodicalId":48650,"journal":{"name":"Endocrinologia Diabetes Y Nutricion","volume":"72 5","pages":"Article 501562"},"PeriodicalIF":1.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144106055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-05-01DOI: 10.1016/j.endien.2025.501545
Luis García Pascual , Carlos Puig-Jové , Andreu Simó-Servat , Lluís García-González
Background and objective
The impact of multifocality on the prognosis of patients with papillary thyroid cancer is relevant when considering the choice of initial surgical treatment by hemithyroidectomy or total thyroidectomy. The aim of the study is to determine the prevalence of multifocality in our setting, its predictive markers and the rates of persistence, recurrence and mortality associated with papillary thyroid cancer with a low risk of recurrence in order to infer the most appropriate initial surgical treatment.
Patients and method
Retrospective observational cross-sectional study of 85 total thyroidectomies.
Results
Prevalences: unifocal carcinoma: 68.2%; multifocal: 31.8%. Predictive markers of multifocality: multinodular ultrasound pattern (OR:17.069, 95% CI:2.989−97.454) and non-incidental finding (OR:7.569, 95% CI:2.363−24.242). In 66.6% of multifocal cases there was bilateral involvement, all of them had a bilateral multinodular ultrasound pattern. Multifocal cases received postoperative radioiodine more frequently (p < 0.001). During the follow-up of 95.5 ± 32.2 months there was one case of persistence and one of recurrence, both in the multifocal group (p:ns), at 12 and 71 months of follow-up. There was no mortality.
Conclusions
This is the first study in our country to estimate the prevalence of multifocality in papillary carcinoma with a low risk of recurrence and to show an excellent prognosis, with no differences compared to unifocal cases, considering that all cases have been treated with total thyroidectomy, but multifocal cases with radioiodine more frequently. Hemithyroidectomy could offer a similar prognosis to total thyroidectomy in cases with an ultrasound pattern of a single or unilateral multinodular nodule, but not in cases of bilateral multinodular thyroid.
{"title":"Multifocality of papillary thyroid carcinoma with low risk of recurrence: Prevalence, predictive markers, prognostic significance and initial surgical treatment","authors":"Luis García Pascual , Carlos Puig-Jové , Andreu Simó-Servat , Lluís García-González","doi":"10.1016/j.endien.2025.501545","DOIUrl":"10.1016/j.endien.2025.501545","url":null,"abstract":"<div><h3>Background and objective</h3><div>The impact of multifocality on the prognosis of patients with papillary thyroid cancer is relevant when considering the choice of initial surgical treatment by hemithyroidectomy or total thyroidectomy. The aim of the study is to determine the prevalence of multifocality in our setting, its predictive markers and the rates of persistence, recurrence and mortality associated with papillary thyroid cancer with a low risk of recurrence in order to infer the most appropriate initial surgical treatment.</div></div><div><h3>Patients and method</h3><div>Retrospective observational cross-sectional study of 85 total thyroidectomies.</div></div><div><h3>Results</h3><div>Prevalences: unifocal carcinoma: 68.2%; multifocal: 31.8%. Predictive markers of multifocality: multinodular ultrasound pattern (OR:17.069, 95% CI:2.989−97.454) and non-incidental finding (OR:7.569, 95% CI:2.363−24.242). In 66.6% of multifocal cases there was bilateral involvement, all of them had a bilateral multinodular ultrasound pattern. Multifocal cases received postoperative radioiodine more frequently (<em>p</em> < 0.001). During the follow-up of 95.5 ± 32.2 months there was one case of persistence and one of recurrence, both in the multifocal group (p:ns), at 12 and 71 months of follow-up. There was no mortality.</div></div><div><h3>Conclusions</h3><div>This is the first study in our country to estimate the prevalence of multifocality in papillary carcinoma with a low risk of recurrence and to show an excellent prognosis, with no differences compared to unifocal cases, considering that all cases have been treated with total thyroidectomy, but multifocal cases with radioiodine more frequently. Hemithyroidectomy could offer a similar prognosis to total thyroidectomy in cases with an ultrasound pattern of a single or unilateral multinodular nodule, but not in cases of bilateral multinodular thyroid.</div></div>","PeriodicalId":48650,"journal":{"name":"Endocrinologia Diabetes Y Nutricion","volume":"72 5","pages":"Article 501545"},"PeriodicalIF":1.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144086518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-05-01DOI: 10.1016/j.endien.2025.501544
María Fernanda Reinoso Gomezcoello , Isabel Pavón de Paz , Cristina Navea Aguilera , Belén Gil Fournier , Ana María Bueno Sanchez , Guadalupe Guijarro de Armas , María Merino Viveros , Jose Antonio Rosado Sierra , Paloma Iglesias Bolaños , María Durán Martínez
Osteogenesis imperfecta (OI) is a rare inherited connective tissue disorder. It is characterized by short stature, fragility and decreased bone mass, which leads to multiple and recurrent fractures after low-energy trauma, which generates susceptibility to long bone deformity and vertebral compression. There are several types of OI, with types I to IV, in which the COL1A1 and COL1A2 genes are affected, being the most frequent. In recent years, the discovery of new forms of OI has led to research into the pathways critical aspects of bone metabolism, with new genes involved being identified. The mutation in IFITM5 has been identified as the cause of OI type V, of autosomal dominant inheritance. OI type V has distinctive clinical features including the development of hypertrophic callus after fracture, early calcification of the interosseous membrane in the forearm, and the presence of hyperdense metaphyseal bands.
The case of a patient with a novo mutation in IFITM5 is presented.
{"title":"Osteogenesis imperfecta type V: About a clinical case","authors":"María Fernanda Reinoso Gomezcoello , Isabel Pavón de Paz , Cristina Navea Aguilera , Belén Gil Fournier , Ana María Bueno Sanchez , Guadalupe Guijarro de Armas , María Merino Viveros , Jose Antonio Rosado Sierra , Paloma Iglesias Bolaños , María Durán Martínez","doi":"10.1016/j.endien.2025.501544","DOIUrl":"10.1016/j.endien.2025.501544","url":null,"abstract":"<div><div>Osteogenesis imperfecta (OI) is a rare inherited connective tissue disorder. It is characterized by short stature, fragility and decreased bone mass, which leads to multiple and recurrent fractures after low-energy trauma, which generates susceptibility to long bone deformity and vertebral compression. There are several types of OI, with types I to IV, in which the <em>COL1A1</em> and <em>COL1A2</em> genes are affected, being the most frequent. In recent years, the discovery of new forms of OI has led to research into the pathways critical aspects of bone metabolism, with new genes involved being identified. The mutation in <em>IFITM5</em> has been identified as the cause of OI type V, of autosomal dominant inheritance. OI type V has distinctive clinical features including the development of hypertrophic callus after fracture, early calcification of the interosseous membrane in the forearm, and the presence of hyperdense metaphyseal bands.</div><div>The case of a patient with a novo mutation in <em>IFITM5</em> is presented.</div></div>","PeriodicalId":48650,"journal":{"name":"Endocrinologia Diabetes Y Nutricion","volume":"72 5","pages":"Article 501544"},"PeriodicalIF":1.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144086522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-04-01DOI: 10.1016/j.endien.2025.101539
Laura Cuadrado Clemente , María Miguélez González , Patricia Cabrera García , Mercedes Noval Font , Élida Alfaro Gandarillas , Marcelino Gómez Balaguer , Nieves Palacios Gil de Antuñano
Introduction
The participation of transgender women (TW) in high-level competitive sports increases every year, as does the interest of sports organizations in finding solutions that allow their inclusion without compromising the principle of equity governing high-level sports. However, the binary categorization of sports, influenced by the impact of sex hormone on physical performance, creates challenges for the inclusion of TW in the female category. This study aimed to understand the impact of gender-affirming hormone therapy (GAHT) on various athletic performance variables and to compare results with those obtained in cisgender populations.
Methods
Review of cross-sectional and longitudinal studies that included TW (preferably athletes) undergoing GAHT.
Results
Significant decreases in hematocrit, total serum testosterone, lean body mass, strength, and muscle area were observed after 12 mo of GAHT, with increases in fat mass. Grip strength was higher in TW compared to cisgender females (CW) in the long term. TW showed better performance in sports involving the upper body.
Conclusions
At least 2 years of postpubertal GAHT are necessary to achieve a significant reduction in the effects of male hormones on various physiological parameters. The scientific evidence regarding the impact of GAHT on physical performance is insufficient. Long-term studies are needed, incorporating new biomarkers and morphofunctional parameters, to allow for comparisons of athletic performance across different disciplines between TW and CW.
{"title":"Transgender women and competitive sports: Considerations from Endocrinology","authors":"Laura Cuadrado Clemente , María Miguélez González , Patricia Cabrera García , Mercedes Noval Font , Élida Alfaro Gandarillas , Marcelino Gómez Balaguer , Nieves Palacios Gil de Antuñano","doi":"10.1016/j.endien.2025.101539","DOIUrl":"10.1016/j.endien.2025.101539","url":null,"abstract":"<div><h3>Introduction</h3><div>The participation of transgender women (TW) in high-level competitive sports increases every year, as does the interest of sports organizations in finding solutions that allow their inclusion without compromising the principle of equity governing high-level sports. However, the binary categorization of sports, influenced by the impact of sex hormone on physical performance, creates challenges for the inclusion of TW in the female category. This study aimed to understand the impact of gender-affirming hormone therapy (GAHT) on various athletic performance variables and to compare results with those obtained in cisgender populations.</div></div><div><h3>Methods</h3><div>Review of cross-sectional and longitudinal studies that included TW (preferably athletes) undergoing GAHT.</div></div><div><h3>Results</h3><div>Significant decreases in hematocrit, total serum testosterone, lean body mass, strength, and muscle area were observed after 12 mo of GAHT, with increases in fat mass. Grip strength was higher in TW compared to cisgender females (CW) in the long term. TW showed better performance in sports involving the upper body.</div></div><div><h3>Conclusions</h3><div>At least 2 years of postpubertal GAHT are necessary to achieve a significant reduction in the effects of male hormones on various physiological parameters. The scientific evidence regarding the impact of GAHT on physical performance is insufficient. Long-term studies are needed, incorporating new biomarkers and morphofunctional parameters, to allow for comparisons of athletic performance across different disciplines between TW and CW.</div></div>","PeriodicalId":48650,"journal":{"name":"Endocrinologia Diabetes Y Nutricion","volume":"72 4","pages":"Article 101539"},"PeriodicalIF":1.8,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143789165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-04-01DOI: 10.1016/j.endien.2025.501547
Óscar Moreno-Perez , Inés Modrego-Pardo
{"title":"Trans and cis women in sport: Citius, altius, fortius, sed aequitas","authors":"Óscar Moreno-Perez , Inés Modrego-Pardo","doi":"10.1016/j.endien.2025.501547","DOIUrl":"10.1016/j.endien.2025.501547","url":null,"abstract":"","PeriodicalId":48650,"journal":{"name":"Endocrinologia Diabetes Y Nutricion","volume":"72 4","pages":"Article 501547"},"PeriodicalIF":1.8,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143722080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号